GlassScriptPhysician profile
Roselle D Mesmer
NPI 1679547293
$3,610.17
in general payments reported to CMS, 2019-2025
28 companies · $1,187 in 2025
The $1,187 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $84.03 · 2021: $156 · 2022: $298 · 2023: $432 · 2024: $1,123 · 2025: $1,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,741.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $477.31 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $439.59 | 2022-2025 | Jardiance |
| Pfizer INC. | $360.92 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $311.12 | 2019-2025 | |
| Amgen INC. | $255.37 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $192.83 | 2024-2025 | Cardiomems, Mitraclip |
| Daiichi Sankyo INC. | $174.01 | 2023-2025 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $172.24 | 2019-2024 | Eliquis, Camzyos |
| Bridgebio Pharma, INC. | $169.18 | 2025 | Attruby |
| Esperion Therapeutics, INC. | $161.75 | 2024-2025 | Nexletol, Nexlizet |
| Cleerly, INC. | $127.07 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Agepha Pharma Fz LLC | $99.29 | 2025 | Lodoco |
| Scpharmaceuticals INC. | $85.76 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $82.73 | 2024 | Arcalyst |
| Zoll Respicardia, INC. | $74.80 | 2023 | Remede System |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $69.11 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $52.41 | 2019-2025 | Lifevest |
| Inspire Medical Systems, INC. | $51.63 | 2024 | Inspire |
| Alnylam Pharmaceuticals INC. | $46.69 | 2025 | Onpattro |
| Sanofi-Aventis U.S. LLC | $31.21 | 2024 | |
| Abiomed | $29.34 | 2023 | Impella |
| Boston Scientific Corporation | $27.21 | 2025 | Varithena Administration Pack |
| Kestra Medical Technology Services, INC. | $23.08 | 2025 | Assure Wcd |
| Heartflow, INC. | $22.38 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $21.69 | 2025 | Evkeeza |
| Merck Sharp & Dohme LLC | $21.34 | 2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $15.90 | 2025 | Farxiga |
| Amarin Pharma, INC. | $14.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roselle Mesmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.